{"id":"NCT04971109","sponsor":"SIGA Technologies","briefTitle":"Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-29","primaryCompletion":"2023-05-12","completion":"2023-05-12","firstPosted":"2021-07-21","resultsPosted":"2024-10-23","lastUpdate":"2024-12-27"},"enrollment":467,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Smallpox"],"interventions":[{"type":"DRUG","name":"TPOXX","otherNames":["tecovirimat"]},{"type":"OTHER","name":"TPOXX Placebo","otherNames":["Placebo"]}],"arms":[{"label":"TPOXX","type":"ACTIVE_COMPARATOR"},{"label":"TPOXX Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.","primaryOutcome":{"measure":"Cmin","timeFrame":"28 days","effectByArm":[{"arm":"TPOXX Pharmacokinetic Population Day 28","deltaMin":792,"sd":52.5}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":369},"commonTop":["Headache","Nausea","Diarrhoea","Vomiting","Upper respiratory tract infection"]}}